About Themis Bioscience
Themis Bioscience is an international biotech company that successfully develops vaccines against emerging and specialist indications.
Exploiting the full potential of our proprietary Themaxyn® platform we are able to identify and rapidly advance vaccine candidates at various stages of development. Based on a well-proven base technology, the Themaxyn® platform offers both, an excellent safety profile and a validated manufacturing process.
Themis Bioscience was founded in 2009 by a group of internationally renowned vaccine and biotech executives in Vienna, Austria. In 2014 Themis successfully completed a phase I clinical trial with our Chikungunya vaccine in Austria. Themis continues to head the race for preventing emerging infectious diseases and started a phase II clinical trial with our Chikungunya vaccine in 2016 and a phase I clinical trial with our Zika vaccine in 2017.
- Founding: 2009
- Focus : Service
- Industry : Biotechnology
News about Themis Bioscience
27-May-2020 | business & finance
Vienna vaccine start-up to be acquired by MSD
Acquisition is expected to accelerate the development of a COVID-19 vaccine candidate
30-Nov-2016 | business & finance
Zika & Chikungunya Vaccine Development Boosted By Cash Injection
Themis Bioscience successfully closed 10 Mio EUR financing round